Werewolf Therapeutics annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Werewolf Therapeutics Capital Expenditures (CapEx) Growth & History (HOWL)
Werewolf Therapeutics's capital expenditures (capex) was $0 for fiscal 2025.
View full Werewolf Therapeutics company overviewWerewolf Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | −$254,000 | — |
| 2024 | 2024-12-31 | $254,000 | −$515,000 | −66.97% |
| 2023 | 2023-12-31 | $769,000 | −$2.8M | −78.70% |
| 2022 | 2022-12-31 | $3.6M | $3.1M | +625.10% |
| 2021 | 2021-12-31 | $498,000 | −$62,000 | −11.07% |
| 2020 | 2020-12-31 | $560,000 | — | — |
Werewolf Therapeutics quarterly capital expenditures (capex)
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $0 | −$123,000 | — |
| Q3 2025 | 2025-09-30 | $0 | −$3,000 | — |
| Q2 2025 | 2025-06-30 | $0 | −$17,000 | — |
| Q1 2025 | 2025-03-31 | $0 | −$111,000 | — |
| Q4 2024 | 2024-12-31 | $123,000 | −$75,000 | −37.88% |
| Q3 2024 | 2024-09-30 | $3,000 | −$218,000 | −98.64% |
| Q2 2024 | 2024-06-30 | $17,000 | −$165,000 | −90.66% |
| Q1 2024 | 2024-03-31 | $111,000 | −$57,000 | −33.93% |
| Q4 2023 | 2023-12-31 | $198,000 | −$320,000 | −61.78% |
| Q3 2023 | 2023-09-30 | $221,000 | −$1.7M | −88.69% |
| Q2 2023 | 2023-06-30 | $182,000 | −$929,000 | −83.62% |
| Q1 2023 | 2023-03-31 | $168,000 | $140,000 | +500.00% |
| Q4 2022 | 2022-12-31 | $518,000 | $246,000 | +90.44% |
| Q3 2022 | 2022-09-30 | $2.0M | $1.9M | +1815.69% |
| Q2 2022 | 2022-06-30 | $1.1M | $1.0M | +900.90% |
| Q1 2022 | 2022-03-31 | $28,000 | $15,000 | +115.38% |
| Q4 2021 | 2021-12-31 | $272,000 | $263,000 | +2922.22% |
| Q3 2021 | 2021-09-30 | $102,000 | $45,000 | +78.95% |
| Q2 2021 | 2021-06-30 | $111,000 | $66,000 | +146.67% |
| Q1 2021 | 2021-03-31 | $13,000 | −$436,000 | −97.10% |
| Q4 2020 | 2020-12-31 | $9,000 | — | — |
| Q3 2020 | 2020-09-30 | $57,000 | — | — |
| Q2 2020 | 2020-06-30 | $45,000 | — | — |
| Q1 2020 | 2020-03-31 | $449,000 | — | — |
Werewolf Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Werewolf Therapeutics's capital expenditures (capex) decreased from $560,000 to $0, a change of −$560,000. The latest reported quarter, Q4 2025, shows $0.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Werewolf Therapeutics source filings ↗